NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.

Author(s): Wludarski SC, Lopes LF, Berto E Silva TR, Carvalho FM, Weiss LM, Bacchi CE

Publication: Appl Immunohistochem Mol Morphol, 2011, Vol. 19, Page 112-8

PubMed ID: 20930616 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to compare HER2 immunohistochemical (IHC) and fluorescence in-situ hybridization (FISH) results in breast cancer tissue specimens.

Conclusion of Paper

FISH and IHC staining results showed overall concordance rates of 98.4% for HER2 positive and negative specimens. Very low concordance rates were found between a reference laboratory and local laboratories for HER2 IHC analysis.

Studies

  1. Study Purpose

    The purpose of this study was to compare HER2 IHC and FISH results for breast carcinoma specimens and to determine factors leading to discordant IHC results between reference and local laboratories.

    Summary of Findings:

    Out of 2000 specimens examined, FISH results were inconclusive for 218 specimens predominantly due to inadequate preservation of tissue. Overall concordance was 98.4% for HER2 positive and negative cases by IHC and FISH. Specimens found to be HER2 equivocal by IHC staining were negative (nonamplified) for HER-2 by FISH 69.8% of the time and positive (amplified) by FISH 30.2% of the time. Between the reference laboratory and local laboratories, HER2 immunostaining results were concordant 6.2%, 14.0%, 84.9%, and 43.8% of the time for scores of 0, 1+, 2+, and 3+, respectively. 27 of the 247 cases (10.9%) scored as 0 or 1+ (negative) by the reference laboratory were scored as 3+ (positive) by local laboratories, and an additional 173 of these cases (70.0%) were scored as 2+ (equivocal) by local laboratories. Of note, information regarding the antibodies used for HER2 IHC analysis was not provided by 55.8% of the local laboratories, while all specimens were analyzed with the SP3 antibody at the reference laboratory. Further, information about fixative and fixation time was not provided by 62.6% of the local laboratories.

    Biospecimens
    Preservative Types
    • Formalin
    Diagnoses:
    • Neoplastic - Carcinoma
    Platform:
    AnalyteTechnology Platform
    Protein Immunohistochemistry
    DNA FISH
    Morphology Light microscopy
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Immunohistochemistry Specific Technology platform FISH
    Immunohistochemistry Specific Targeted peptide/protein HER2
    Immunohistochemistry Specific Type of antibody SP3
    Unspecified
    CB11
    DAKO polyclonal
    5A2
    HercepTest
    A0485
    Unspecified polyclonal
    TAB250
    EP1045Y
    HER-24
    CBE1
    10A7
    FISH Specific Targeted nucleic acid HER2

You Recently Viewed  

News and Announcements

  • Most Downloaded SOPs in 2024

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • More...